Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

13  Enrolling
15  Total Trials
Pinned
Conditions: Obesity, Overweight, Type 2 Diabetes, Sleep Apnea
Trial Name
TRIUMPH-2
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Obesity, Overweight and Cardiovascular Disease
Trial Name
TRIUMPH-3
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Obesity, Overweight, Osteoarthritis, Sleep Apnea
Trial Name
TRIUMPH-1
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Obesity, Overweight and Osteoarthritis of the Knee
Trial Name
TRIUMPH-4
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Obesity
Drugs: Mazdutide
Age
18 - 75 years
Phase
II
Pinned
Conditions: Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
Trial Name
ACHIEVE-4
Drugs: Orforglipron (LY3502970), Insulin Glargine
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes, Obesity
Drugs: Tirzepatide (LY3298176)
Age
18 - 75 years
Phase
II
Conditions: Overweight, Obesity
Drugs: LY3841136, Tirzepatide
Age
18 - 65 years
Phase
I
Conditions: Obesity
Drugs: retatrutide
Age
18 - 60 years
Phase
I
Conditions: Obesity, Overweight
Drugs: LY3841136
Age
18 - 75 years
Phase
II
Conditions: Obesity, Overweight, Chronic Kidney Disease with or without Type 2 Diabetes
Trial Name
TREASURE-CKD
Drugs: Tirzepatide
Age
≥18 years
Phase
II
Conditions: Obesity
Drugs: Tirzepatide
Age
12 - 17 years
Phase
III
Conditions: Obesity, Overweight, Chronic kidney disease
Drugs: retatrutide
Age
≥18 years
Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
2 
Completed Enrollment
15  Total Trials
Conditions: Obesity
Trial Name
ATTAIN-1
Drugs: Orforglipron
Age
≥18 years
Phase
III
Conditions: Obesity
Trial Name
SURMOUNT-MMO
Drugs: Tirzepatide
Age
≥40 years
Phase
III